Oligometastatic prostate cancer: The game is afoot. (February 2019)

• Record Type: Journal Article
• Authors: Lancia, Andrea; Zilli, Thomas; Achard, Verane; Dirix, Piet; Everaerts, Wouter; Gomez-Iturriaga, Alfonso; Ingrosso, Gianluca; Liefhooghe, Nick; Miralbell, Raymond; Siva, Shankar; Van der Eecken, Kim; Ost, Piet
• Is Part Of: Cancer treatment reviews. Volume 73(2019)
• Page Start: 84
• Page End: 90
• Publication Date: 2019-02
• Subjects: Prostate cancer -- Oligometastatic -- Radiotherapy -- De novo -- Oligorecurrent -- Oligoprogressive; Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2019.01.005
• Languages: English
• ISSNs: 0305-7372

Abstract

Highlights: The biology of oligometastatic prostate cancer needs to be fully decoded. PSMA PET is a reliable tool in the recognition of this state of disease. Targeting primary tumor seems to be beneficial in a subgroup of patients. First prospective data confirm the performance of metastasis-directed therapies. Abstract: Oligometastatic prostate cancer represents an intermediate state between a localized tumor and widespread metastatic disease. Its specific clinical features suggest the existence of a distinct biology which still needs to be elucidated. New imaging techniques like prostate specific membrane antigen (PSMA) PET scans have shown to perform well in the staging and restaging of this category of patients, at different phases of disease evolution. Despite limited prospective evidence, metastasis-directed therapies (MDT) are emerging as valid treatment options able to postpone systemic therapies and probably improve survival outcome. The aim of this review is to shed light on the clinical scenario of prostate cancer patients with limited metastatic disease burden and highlight the role of MDT strategies in this setting.